2 stories mentioning OPKUpdated 43d ago
Every FINWIRES story that references OPK, newest first.
OPKO Health (OPK) has an average rating of overweight and mean price target of $3.76 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $1.08, Change: $-0.13, Percent Change: -10.74%
OPKO Health's (OPK) ModeX Therapeutics said Wednesday it has dosed patients with MDX2003 for the potential treatment of relapsed or refractory B-cell lymphoma.The trial includes dose-escalation and dose-expansion phases, the company said.Preclinical proof-of-concept data, along with analyses supporting clinical dose selection, were presented at the 2025 American Society of Hematology annual meeting and the ESMO Targeted Anticancer Therapies Congress 2026, the company said.Price: $1.24, Change: $+0.02, Percent Change: +1.64%
